SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-025786
Filing Date
2021-05-12
Accepted
2021-05-12 16:01:50
Documents
54
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0321_relmadatherap.htm 10-Q 391323
2 CERTIFICATION f10q0321ex31-2_relmada.htm EX-31.2 12966
3 CERTIFICATION f10q0321ex31-1_relmada.htm EX-31.1 12813
4 CERTIFICATION f10q0321ex32-1_relmada.htm EX-32.1 4265
5 CERTIFICATION f10q0321ex32-2_relmada.htm EX-32.2 4026
  Complete submission text file 0001213900-21-025786.txt   2512206

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rlmd-20210331.xml EX-101.INS 272755
7 XBRL SCHEMA FILE rlmd-20210331.xsd EX-101.SCH 38769
8 XBRL CALCULATION FILE rlmd-20210331_cal.xml EX-101.CAL 22680
9 XBRL DEFINITION FILE rlmd-20210331_def.xml EX-101.DEF 174205
10 XBRL LABEL FILE rlmd-20210331_lab.xml EX-101.LAB 348386
11 XBRL PRESENTATION FILE rlmd-20210331_pre.xml EX-101.PRE 183492
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39082 | Film No.: 21914988
SIC: 2834 Pharmaceutical Preparations